New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 10, 2014
11:51 EDTTAL, NFLX, EXEL, WTW, YRCWOptions with increasing implied volatility: YRCW EXEL TAL WTW NFLX
News For YRCW;EXEL;TAL;WTW;NFLX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
November 20, 2014
07:38 EDTEXELThe Federal Energy Regulatory Commission (FERC) to hold a meeting
Subscribe for More Information
06:48 EDTNFLXNetflix's Kelly Merryman to join YouTube, TechCrunch reports
Subscribe for More Information
06:39 EDTNFLXStocks with implied volatility below IV index mean; GNW NFLX
Stocks with implied volatility below IV index mean; Genworth (GNW) 53, Netflix (NFLX) 31 according to iVolatility.
November 19, 2014
19:16 EDTNFLXNetflix orders fourth season of Longmire
Subscribe for More Information
14:25 EDTNFLXOptions Update; November 14, 2014
Subscribe for More Information
13:29 EDTNFLXCharter CEO sees Comcast, Time Warner Cable deal getting done
Subscribe for More Information
09:39 EDTNFLXActive equity options trading on open
Subscribe for More Information
09:38 EDTNFLXCCS Insight predicts Netflix to be acquired next year, FT reports
CCS Insight, a U.K.-based technology research firm, is predicting that a major internet player such as Yahoo (YHOO), Alibaba (BABA) or Google (GOOG) will buy Netflix (NFLX) next year, reported Financial Times. Reference Link
06:34 EDTNFLXNielsen to begin measuring viewing of subscription video services, WSJ reports
Subscribe for More Information
06:00 EDTNFLXStocks with implied volatility below IV index mean; PCLN NFLX
Stocks with implied volatility below IV index mean; Priceline (PCLN) 22, Netflix (NFLX) 29 according to iVolatility.
November 18, 2014
17:40 EDTNFLXNetflix to launch in Australia, New Zealand in March, 2015
Subscribe for More Information
05:57 EDTNFLXStocks with implied volatility below IV index mean; PCLN NFLX
Stocks with implied volatility below IV index mean; Priceline (PCLN) 22, Netflix (NFLX) 30 according to iVolatility.
November 16, 2014
13:12 EDTEXELExelixis announces data from trial of XL888 and vemurafenib
Exelixis announced preliminary results from a phase 1 investigator-sponsored trial, IST, evaluating the safety and activity of XL888, an Exelixis-discovered small molecule oral inhibitor of Heat Shock Protein 90, HSP90, in combination with vemurafenib in patients with unresectable stage III/IV BRAF V600 mutation-positive melanoma. Safety and efficacy results support the further investigation of 90 mg of XL888 twice weekly, BIW and vemurafenib 960 mg twice daily,BID, in additional studies that would include a third agent. The trial results were presented today by Keiran Smalley, Ph.D., an investigator on the trial and an associate professor at H. Lee Moffitt Cancer Center, Tampa, Florida, in a late-breaking oral presentation session at the Society for Melanoma Research 2014 International Congress, which is taking place November 13-16, in Zurich, Switzerland. Based on these results, as well as findings from coBRIM, the phase 3 pivotal trial of cobimetinib, an Exelixis-discovered MEK inhibitor, and vemurafenib in previously untreated metastatic melanoma patients with a BRAF V600 mutation, the Moffitt Center plans to initiate a phase 1b IST of the triple combination of vemurafenib, cobimetinib, and XL888 in a similar patient population. “The BRAF inhibitor vemurafenib is active in BRAF-mutated malignant melanoma, but development of resistance is common. Preclinical studies led by Keiran Smalley, Ph.D. suggested that most BRAF inhibitor resistance mechanisms involve proteins that are clients of HSP90, and the preclinical evaluation of XL888 showed that it is highly active in vemurafenib-resistant melanoma models,” said Jeffrey Weber, MD, Ph.D., director of the Donald A. Adam Comprehensive Melanoma Research Center at the Moffitt Cancer Center and Research Institute in Tampa, FL. “The current phase 1 data show that both drugs can be given together, and compelling initial response results suggest potential cooperative activity.” “About half of metastatic melanoma patients whose tumors harbor a BRAF V600 mutation respond to vemurafenib, but most of them develop resistance and their tumors begin to regrow,” said Michael M. Morrissey, Ph.D., president and chief executive officer of Exelixis. “Multiple mechanisms drive this resistance, and the team at Moffitt found that many of them involve upregulation of HSP90 client proteins that are sensitive to XL888. We look forward to supporting the Moffitt team as they continue to evaluate XL888 as part of our IST program.”
November 14, 2014
17:07 EDTNFLXSoros Fund Management gives quarterly update on stakes
Subscribe for More Information
17:01 EDTNFLXIcahn Associates gives quarterly update on stakes
Subscribe for More Information
16:01 EDTNFLXOptions Update; November 14, 2014
Subscribe for More Information
11:37 EDTNFLXNetflix shuts down public API today, Gigaom reports
Subscribe for More Information
06:19 EDTNFLXStocks with implied volatility below IV index mean; PCLN NFLX
Subscribe for More Information
November 13, 2014
14:50 EDTYRCWLonestar Capital to shut down by mid-2015, WSJ reports
Subscribe for More Information
14:45 EDTYRCWLonestar capital to shut down, DJ reports
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use